The effects of the therapy in a small group of  patients were long-lasting, researchers say, adding to evidence that the approach works for treatment-resistant depression.

The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.

A drug commonly used to treat clinical depression sets its effects in motion by hampering the release of an inhibitory neurotransmitter in mice.